- Home
- OTLK vs LFT Comparison
OTLK vs LFT Comparison
Compare OTLK & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | LFT |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 83.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | LFT |
|---|---|---|
| Price | $2.18 | $1.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 225.7K |
| Earning Date | 12-24-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 10.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $1,505,322.00 | ★ $21,708,246.00 |
| Revenue This Year | N/A | $124.75 |
| Revenue Next Year | $342.80 | N/A |
| P/E Ratio | ★ N/A | $16.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $1.41 |
| 52 Week High | $3.39 | $2.84 |
Technical Indicators
Market Signals| Indicator | OTLK | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 45.83 |
| Support Level | $1.91 | $1.41 |
| Resistance Level | $2.10 | $1.65 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 95.65 | 33.33 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.